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Platelets are critically involved in murine patent ductus arteriosus (PDA) closure. To date,
the clinical significance of these findings in human preterm infants with PDA is still
controversial. We discuss the available study data on the role of platelets for PDA closure
in preterm infants: Several mostly retrospective studies have yielded conflicting results on
whether thrombocytopenia contributes to failed spontaneous ductal closure. The same
applies to investigations on the role of thrombocytopenia as a risk factor for unsuccessful
ductus arteriosus closure by pharmacological treatment with cyclooxygenase inhibitors.
Nonetheless, recent meta-analyses have concluded that thrombocytopenia constitutes
an independent risk factor for both failed spontaneous and pharmacological PDA
closure in preterm infants. However, the available investigations differ in regard to patient
characteristics, diagnostic strategies, and treatment protocols. Several studies suggest
that impaired platelet function rather than platelet number is critically involved in failure of
ductus arteriosus closure in the preterm infant. A recent randomized-controlled trial on
platelet transfusions in preterm infants with PDA failed to show any benefit for liberal vs.
restrictive transfusion thresholds on PDA closure rates. Importantly, liberal transfusions
were associated with an increased rate of intraventricular hemorrhage, and thus should
be avoided. In conclusion, the available evidence suggests that thrombocytopenia and
platelet dysfunction contribute to failure of spontaneous and pharmacological PDA
closure in preterm infants. However, these platelet effects on PDA seem to be of only
moderate clinical significance. Furthermore, platelet transfusions in thrombocytopenic
preterm infants in order to facilitate PDA closure appear to cause more harm than good.
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Sallmon et al. Platelets and PDA
INTRODUCTION
After birth, a persistently patent ductus arteriosus (PDA) is
usually associated with left-to-right shunt; and subsequently,
variable degrees of pulmonary overcirculation, systemic
hypotension, and malperfusion (1). In preterm infants, the
consequences of a hemodynamically significant PDA (hsPDA)
are frequently associated with several severe cardiopulmonary
complications such as left ventricular volume overload,
pulmonary edema, impairment of lung compliance, and
abdominal-renal malperfusion due to the ductal steal (1–3).
Thus, understanding the mechanisms that contribute to ductus
arteriosus (DA) closure is of pivotal importance in order to
provide tailored care to at-risk neonates (4, 5).
In 2010, Echtler et al. (6) reported that platelets contribute
to ductal closure and subsequent vascular remodeling in mice.
By means of intravital microscopy, they showed that platelets
are recruited to the luminal aspect of the ductal endothelium
within minutes after birth and that formation of a platelet-plug
within the DA contributes to ductal remodeling. In addition,
by using two murine models of genetic disruption of platelet
biogenesis and function (Nfe−/− and Itga2b−/− mice), the
authors demonstrated that platelet dysfunction was associated
with hsPDA (as assessed by a quantification of pulmonary
blood flow using radiolabeled microspheres). Similar results
were observed when an antibody directed against platelet
collagen receptor GPVI was administered, thus indicating that
both GPVI and GPIIb/IIIa contribute to platelet-triggered DA
closure. In addition, the authors showed that administration
of cyclooxygenase inhibitors (ibuprofen or indomethacin) was
not sufficient to compensate for impaired platelet function in
their murine model (6). Of note, mouse ductuses are remarkably
similar to human ductuses, but they lack prominent intimal
cushions, which protrude into the vessel lumen and contribute
to vessel closure and permanent remodeling. Therefore, platelets
may play a larger role in mouse vs. human duct occlusion due to
the lack of intimal cushions.
Taken together, the experimental results above suggest that
platelets play a pivotal role in ductus arteriosus closure. However,
the clinical significance of these findings in human preterm
infants is still controversial and has not been confirmed
in vivo (7). Here, we discuss the available data on the current
controversy on platelets and PDA and their clinical implications
in preterm infants.
THE EFFECTS OF THROMBOCYTOPENIA




Low platelet counts are frequently observed among preterm
infants (8, 9) and the role of platelets in spontaneous or
pharmacological PDA closure has been explored by several
groups yielding conflicting results. In addition to their animal
results, Echtler et al. (6) also reported on a small cohort of
123 preterm infants, in which low platelet counts within the
first 24 h after birth were associated with a higher incidence
of PDA. However, another small study (n = 211) failed to
confirm these results in a Japanese cohort of preterm infants
(10). Similarly, Shah et al. could not find any association between
low platelet counts during the 1st week of life and incidence of
PDA, but they observed a decreased incidence of PDA when
platelet counts were consistently > 230/nL. Of note, all infants
in this study received prophylactic indomethacin within the
first 15 h of life (11). Consistently, two other studies did not
confirm any significant associations between thrombocytopenia
and a higher incidence of PDA/hsPDA or later PDA treatment
failure (12, 13). In contrast, data from several other investigators
suggest that thrombocytopenia within the 1st week of life did
contribute to prolonged ductal patency (14–17) and a meta-
analysis from 2015, which included 11 cohort studies involving
3,479 infants, concluded that low platelet counts within the 1st
day(s) of life were marginally but significantly associated with
PDA/hsPDA (18).
In terms of platelets and pharmacological DA closure, several
authors reported that low platelet counts within the 1st day(s)
of life were not predictive of later pharmacological treatment
failure in infants with hsPDA (14, 15, 19, 20). However,
recent studies have yielded conflicting results on whether a
positive association between higher platelet counts just before or
during cyclooxygenase inhibitor therapy and PDA closure rates
exists. For example, while platelet counts before pharmacological
therapy were not predictive of PDA treatment success rates,
low platelet counts during pharmacological treatment were
associated with an increased rate of treatment failure in a cohort
of 471 preterm infants. In this study, only infants with hsPDA
on day of life 3–5 received cyclooxygenase inhibitor treatment
(hemodynamically significant if (i) a respiratory setback with
a supplemental oxygen requirement >30% and/or mechanical
ventilation, (ii) a LA/Ao ratio≥1.4 in the echocardiogram and/or
(iii) ductal diameter ≥2.5mm, and/or (iv) a decreased end-
diastolic flow in the anterior cerebral artery with a resistance
index ≥0.85) (21). In addition, two reports on indomethacin
found that higher platelet counts just before treatment initiation
were associated with higher success rates (22, 23), while others
were unable to demonstrate such an association (24, 25).
Nonetheless, similar to the results obtained for spontaneous
ductal closure (18), a recent meta-analysis (eight studies
including 1,087 infants) revealed a moderate but significant
association between pretreatment thrombocytopenia and failure
of pharmacological PDA closure (26). Of note, cyclooxygenase
inhibitors are known to adversely affect platelet plug formation in
adults. The few available data from preterm infants suggest that
inhibition of platelet plug formation in neonates may occur, but
seem to be of limited clinical significance under cyclooxygenase
inhibitor treatment (27). However, one might speculate that even
moderate alterations in platelet function may become relevant in
severely thrombocytopenic infants.
Taken together, the combined evidence suggests the existence
of a moderate but detectable impact of platelets on both
spontaneous and pharmacological PDA closure in preterm
infants. However, it should be noted, that most studies were
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retrospective in nature, and thus, even the positive studies
cannot conclude on any causality as relevant confounding
factors might have been missed by the analyses. In addition,
the remarkable heterogeneity in study design (selection criteria,
genetic background, and timing of platelet counts), diagnostic
protocols (timing of echocardiography and criteria used to
define hemodynamic significance), and differences in treatment
approaches (timing, dosage, and application route) may have
influenced the comparability of the available studies (18, 26, 28).
A recent randomized-controlled trial on platelet transfusions
addressed the clinical implications of the aforementioned
associations between low platelet counts and failure of hsPDA
closure in preterm infants (<35 weeks of gestational age)
(29). The authors compared liberal platelet-transfusion criteria
(platelet counts were maintained >100,000 /µL) vs. restrictive
criteria (platelet count < 20,000/µL, clinical bleed, platelet
count < 50,000/µL and requiring a major non-neurosurgical
procedure, or platelet count < 100,000/µL and requiring a
neurosurgical procedure), and the impact of either approach on
hsPDA closure (n = 22 in each group). All subjects received
standard co-treatment with nonsteroidal anti-inflammatory
drugs. There was no significant difference in the time required
to achieve PDA closure (median of 72 h in both groups, p =
0.697). However, 41% of all infants in the liberal transfusion
group were found to develop intraventricular hemorrhage (IVH,
any grade), while IVH was only seen in 4.5% of the infants
allocated to the restrictive transfusion group (p = 0.009) (29).
Potential mechanisms that might contribute to the increased
rate of IVH in liberally transfused infants include hemodynamic
alterations due to volume challenge by transfusions and a
possible modification of periventricular capillary function by
transfused platelets.
PLATELET INDICES AND PDA
Considering the contradictory results on platelet counts and
their possible associations with PDA incidence and treatment
success, several experts have speculated that platelet indices
such as mean platelet volume (MPV), platelet distribution width
(PDW), or platelet mass (calculated by multiplying platelet
count by MPV) may be more useful in predicting PDA and/or
treatment response. Alyamac Dizdar et al. (14) reported that
high PDW values within the first 3 days of life were associated
with PDA. Similar to Dani et al. (15) they did not find any
association between MPV and PDA incidence or treatment
response. Another group reported consistently higher PDW
values in infants with hsPDA within the first 24 h after birth,
but did not find any association between MPV, platelet mass,
or platelet counts and hsPDA, respectively (20). However, such
an association between higher platelet mass and MPV and
hsPDA closure has been reported by others (30). Another group
from Turkey did not find any relationship between platelet
counts, MPV, or platelet mass and successful hsPDA closure
by ibuprofen (19). In addition to MPV, PDW, and platelet
mass, other hematologic indices, such as red cell distribution
width-to-platelet ratio (RPR) and platelet-to-lymphocyte-ratio
(PLR) have been proposed as markers for hsPDA and treatment
response (31–33).
In summary, the aforementioned studies (and recent meta-
analyses) on platelet indices and PDA have revealed inconsistent
or even conflicting results, which were probably, at least in part,
due to differences in study designs, treatment protocols, and the
definition of hsPDA (28, 34). Furthermore, hematologic indices
might be affected by several conditions, such as inflammation,
hypoxia and/or volume status, and thus likely represent surrogate
markers of neonatal well-being rather than being specific
indicators of PDA/hsPDA, e.g., higher PDW values are thought
to reflect altered platelet function/activation (35).
PLATELET FUNCTION AND PDA CLOSURE
IN PRETERM INFANTS
Previous studies investigating the role of thrombocytopenia in
spontaneous or pharmacological ductus arteriosus closure
have provided controversial results. However, several
investigations have consistently identified sepsis/inflammation,
lower gestational age, and feto-maternal conditions such as
preeclampsia as risk factors for failure of DA closure in preterm
infants. Since all these factors are associated with altered platelet
function, it has been speculated that platelet function, rather
than platelet number, is the key determinant of PDA closure
in neonates (36, 37). A significant association between lower
platelet count, higher CRP level and incidence of PDA has been
demonstrated, with CRP being the only independent predictive
factor for PDA in a regression model (38). These findings
support the theory of a combined effect of one common cause
(e.g., sepsis) on both platelet number and function and failure
of DA closure. A proteomics-based study on human neonatal
plasma identified six differentially expressed proteins (platelet
factor 4, fibrinogen, von Willebrand factor, collagen, mannose
binding lectin-associated serine protease-2, fibronectin), which
were associated with PDA. Interestingly, those proteins are
closely related to platelet activation and plasmatic coagulation
cascades (39).
Recent observational studies have also confirmed a
relationship between altered platelet function and failure of
DA closure in human preterm infants. Collagen-ADP closure
times > 130 s (PFA-100) are more frequently observed in infants
with PDA as compared to those without PDA, and longer
collagen-ADP closure times represent an independent risk
factor for ductal patency (40). In addition, lower median levels
of platelet-derived growth factor (PDGF) were found in those
infants who later required pharmacological PDA therapy vs.
those who did not require such treatment (41). The same group
of authors also proposed the usage of platelet-rich plasma in
preterm infants with PDA as an experimental approach for PDA
treatment (42–44). Recently, other investigators found lower
PDGF levels in very immature infants (22–27 weeks) with failure
of spontaneous DA closure (45). In addition, Ghirardello et al.
(46) assessed thromboelastography at birth in VLBW infants
with PDA (n= 151). In their study, thromboelastography at birth
did not predict persistence of PDA. However, infants who failed
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FIGURE 1 | Structural factors that play a role in ductus arteriosus closure. Illustrated are the structural features known to regulate ductus closure in mice, preterm
infants, and term-gestation infants. Mice have mature smooth muscle cells (pink) that constrict robustly in response to oxygen but lack intimal cushions (yellow), which
may explain why platelets (green) are required for vessel occlusion and remodeling. Term-gestation infants have a thick medial layer composed of mature smooth
muscle cells that are very sensitive to oxygen-induced constriction. They also have prominent vasa vasorum (purple circles) which results in local ischemic areas and
hypoxic signaling during closure. A platelet plug and mononuclear cells (blue circles) adhere to the lumen during closure and promote formation of a permanent seal
and remodeling. In contrast, several structural factors contribute to failed ductal closure in preterm infants. The preterm ductus has an underdeveloped media
containing immature smooth muscle cells and less vasa vasorum, making it less sensitive to oxygen/hypoxia signaling. Preterm vessels also lack prominent intimal
cushions and have preterm platelets. Characteristics of preterm human platelets that are associated with an enhanced vulnerability to dysfunction, which in turn might
contribute to higher rates of ductal patency in immature preterm infants are also listed. ADP, adenosine di-phosphate; GPIIb/IIIa, glycoprotein IIb/IIIa; PAC-1,
procaspase activating compound 1 which detects activated GPIIb/IIIa.
medical treatment exhibited signs of an enhanced fibrinolysis
(46). While the exact mechanisms and the clinical consequences
of these findings are yet to be examined, they further indicate a
role of the neonatal coagulation system in ductal closure.
It should be noted that the hemostatic system and especially
platelet function in infants differ from that of adults—a fact that
needs to be taken into account when designing future studies
on the impact of platelet function on neonatal diseases such
as PDA (47, 48). Despite developmental “defects” in platelet
function, healthy full-term infants show a more effective primary
hemostasis than healthy adults in whole blood tests of primary
hemostasis such as bleeding time and PFA-100 (49). This has been
attributed to several factors, including high levels of large von
Willebrand factor (vWF) multimers, high hematocrit, and high
mean corpuscular volume (MCV) values, which compensate for
the impaired platelet function in newborns (47, 49).
Platelet function may play an even larger role in closure of the
preterm ductus, given that preterm vessels are often structurally
underdeveloped (lack fully-formed intimal cushions) and less
responsive to oxygen-induced vasoconstriction. However, in
preterm infants below 30 weeks of gestational age platelet
function is further impaired when compared to full-term
infants (Figure 1). For example, preterm platelets show a
decreased number of α2-adrenergic receptors, decreased calcium
mobilization, and impaired signal transduction causing a
decreased agonist-induced granule secretion and exposure of the
fibrinogen binding site on the GPIIb/IIIa complex (49). More
immature preterm infants also exhibit lower levels of P-selectin
Frontiers in Pediatrics | www.frontiersin.org 4 February 2021 | Volume 9 | Article 612242
Sallmon et al. Platelets and PDA
expression on resting platelets (50) and lower levels of P-selectin
and PAC-1 following stimulation with platelet agonists (49).
They also show decreased platelet adhesion and aggregation in
response to platelet agonists such as collagen, epinephrine, ADP,
and thrombin and longer bleeding and closure times by PFA-100
(49, 51, 52). Similar results on the developmental maturation of
platelet function have recently been reported in murine fetuses.
Interestingly, these investigators reported rapid platelet aggregate
formation when adult platelets where transfused into the fetal
circulation. However, in line with the later prospective trial by
Kumar et al. (29), a retrospective analysis on the effect of platelet
transfusions on PDA closure rates in preterm infants failed to
demonstrate any influence of transfusions on ductal closure (53).
In addition to developmental differences in platelet function
between preterm infants, term infants and adults, it is known
that newly released platelets (immature platelets) differ in their
functional properties as compared to older, moremature platelets
(54). It has recently been shown that a lower number of
mature platelets during the latter half of the 1st week of life
was associated with PDA in preterm infants, while immature
platelets were not independently associated with PDA (55).
Importantly, a mathematical model of platelet turnover in
preterm infants demonstrated significantly shorter population
survival values for immature platelets and shorter platelet life
spans in thrombocytopenic vs. non-thrombocytopenic neonates,
indicating a preferential depletion of older, more mature platelets
in thrombocytopenic infants (56).
Of note, the interaction of platelets with other circulating
and tissue resident blood cells has been studied in common
cardiovascular diseases such as atherosclerosis, but not in human
PDA. For example, platelet–neutrophil complexes (PNCs) are
increased in patients with acute myocardial infarction, in
association with increased levels of neuronal guidance protein
semaphorin 7A (57). Mononuclear cells contribute to ductal
closure (58, 59), but their direct or paracrine interaction with
platelets and other circulating blood cells in human PDA is still
unclear. Likewise, red blood cells affect bleeding and thrombosis,
and interact with cellular and molecular components of the
hemostatic system; however, platelet-erythrocyte interactions
have not been investigated in preterm infants with PDA (60).
CONCLUSIONS
The identification of platelets as contributors to ductal
closure in neonates represents a conceptual breakthrough
in developmental vascular medicine. Developmentally
regulated platelet-endothelial interactions contribute to
normal cardiovascular transition from fetal to postnatal life
(6, 7, 36). In addition, thrombocytopenia and impaired platelet
function seem to impact spontaneous and pharmacological
PDA closure in preterm infants, linking platelets to a
specific neonatal cardiovascular disease. While the clinical
implications of these findings are still controversial, during
the last decade, they have stipulated further research efforts
on the specific developmental differences between neonatal
and adult megakaryopoiesis, platelet formation and function,
and their respective roles in neonatal health and disease
(61). For example, the role of platelets in retinopathy
of prematurity has been recently elucidated by several
investigators (62–64).
In light of the recently observed practice changes toward a
less frequent and less proactive treatment approach to managing
preterm PDA, clinicians still face the difficult questions on how to
decide which infants will benefit from PDA closure; and on when
and how PDA closure should be attempted or facilitated [(1, 2,
4)—please also refer to other articles in this special issue]. Despite
the experimental and epidemiologic evidence for an association
between platelets and ductal closure, current clinical evidence
strongly suggests, that platelet transfusions for facilitating PDA
closure in preterm thrombocytopenic infants cause more harm
than good (29, 65).
Thus, further research is required to elucidate the complex
interplay between PDA, shunt, circulating blood cells, including
platelets, and adverse outcomes of PDA in order to define
accurate biomarkers and the optimal therapeutic strategies for
this still elusive condition in the most vulnerable population of
preterm infants (1, 66).
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